Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20248738 | 0.93 | PRMT6 (0.48) | P2RY12PRMT6DNPH1P2RY2P2RY1 | |
| SCHEMBL29313477 | 0.93 | PRMT6 (0.48) | P2RY12PRMT6DNPH1P2RY2P2RY1 | |
| SCHEMBL17325427 | 0.93 | ADORA1 (0.49) | P2RY12PRMT6ADORA3ADORA1 | |
| SCHEMBL29769721 | 0.93 | ADORA1 (0.49) | P2RY12PRMT6ADORA3ADORA1 | |
| SCHEMBL19762768 | 0.93 | ADORA1 (0.49) | P2RY12PRMT6ADORA3ADORA1 | |
| SCHEMBL20248740 | 0.93 | ADORA1 (0.49) | P2RY12PRMT6ADORA3ADORA1 | |
| SCHEMBL18937381 | 0.93 | ADORA1 (0.49) | P2RY12PRMT6ADORA3ADORA1 | |
| SCHEMBL17974255 | 0.93 | ADORA1 (0.49) | P2RY12PRMT6ADORA3ADORA1 | |
| SCHEMBL20692151 | 0.93 | ADORA1 (0.49) | P2RY12PRMT6ADORA3ADORA1 | |
| SCHEMBL21356326 | 0.92 | P2RY12 (0.48) | P2RY12PRMT6DNPH1P2RY2P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449211-B2 | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling | Aduro Biotech, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180064745-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10449211-B2 | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling | STING1, IRF3, CGAS | P2RY12 73/4885PRMT6 4017/4885DNPH1 1890/4885 |
| US-20180064745-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | STING1, IRF3, CGAS | P2RY12 81/4885PRMT6 4082/4885DNPH1 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.